Update on rituximab

Annals of the Rheumatic Diseases

Volumn 64, Issue SUPPL. 4, 2005, Pages

  Eisenberg, R ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIGEN; CHIMERIC ANTIBODY; CYCLOPHOSPHAMIDE; METHOTREXATE; NEUTROPHIL CYTOPLASMIC ANTIBODY; PNEUMOCOCCUS VACCINE; RHEUMATOID FACTOR; RITUXIMAB; STEROID; TETANUS TOXOID; TUMOR NECROSIS FACTOR ANTIBODY;

AUTOIMMUNE DISEASE; B CELL LYMPHOMA; B LYMPHOCYTE; CLINICAL TRIAL; CONFERENCE PAPER; CYTOPENIA; DERMATOMYOSITIS; DRUG PROTEIN BINDING; HEPATITIS B; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; POLYNEUROPATHY; PRIORITY JOURNAL; REINFECTION; RHEUMATOID ARTHRITIS; SERUM SICKNESS; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT OUTCOME; WEGENER GRANULOMATOSIS;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; AUTOIMMUNE DISEASES; HUMANS; RANDOMIZED CONTROLLED TRIALS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 27444441270     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2005.042648     Document Type: Conference Paper

References (26)

1. Grillo-Lopez AJ, White CA, Varns C, Shen D, Wei A, McClure A, et al. Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma. Semin Oncol 1999;26(5 Suppl 14):66-73.
2. Tedder TF, Engel P. CD20: a regulator of cell-cycle progression of B lymphocytes. Immunol Today 1994;15:450-4.
3. Riley JK, Sliwkowski MX. CD20: a gene in search of a function. Semin Oncol 2000;27(6 Suppl 12):17-24.
4. O'Keefe TL, Williams GT, Davies SL, Neuberger MS. Mice carrying a CD20 gene disruption. Immunogenetics 1998;48:125-32.
5. Maloney DG. Preclinical and phase I and II trials of rituximab. Semin Oncol 1999;26(5 Suppl 14):74-8.
6. Monson NL, Cravens PD, Frohman EM, Hawker K, Racke MK. Effect of rituximab on the peripheral blood and cerebrospinal fluid B cells in patients with primary progressive multiple sclerosis. Arch Neurol 2005;62:258-64.
7. Hofmeister JK, Cooney D, Coggeshall KM. Clustered CD20 induced apoptosis: src-family kinase, the proximal regulator of tyrosine phosphorylation, calcium influx, and caspase 3-dependent apoptosis. Blood Cells Mol Dis 2000;26:133-43.
8. Clynes RA, Towers TL, Presto LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 2000;6:443-6.
9. Grillo-Lopez AJ. Rituximab: an insider's historical perspective. Semin Oncol 2000;27(6 Suppl 12):9-16.
10. Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004;350:2572-81.
11. Schroder AE, Greiner A, Seyfert C, Berek C. Differentiation of B cells in the nonlymphoid tissue of the synovial membrane of patients with rheumatoid arthritis. Proc Natl Acad Sci U S A 1996;93:221-5.
12. Takemura S, Klimiuk PA, Braun A, Goronzy JJ, Weyand CM. T cell activation in rheumatoid synovium is B cell dependent. J Immunol 2001;167:4710-18.
13. Leandro MJ, Edwards JC, Cambridge G. Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion. Ann Rheum Dis 2002;61:883-8.
14. Keogh KA, Wylam ME, Stone JH, Specks U. Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2005;52:262-8.
15. Levine TD. Rituximab in the treatment of dermatomyositis: an open-label pilot study. Arthritis Rheum 2005;52:601-7.
16. Looney RJ, Anolik J, Sanz I. Treatment of SLE with anti-CD20 monoclonal antibody. Curr Dir Autoimmun 2005;8:193-205.
17. Eisenberg R. SLE-Rituximab in lupus. Arthritis Res Ther 2003;5:157-9.
18. Looney RJ, Anolik JH, Campbell D, Felgar RE, Young F, Arend LJ, et al. B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum 2004;50:2580-9.
19. Anolik JH, Barnard J, Cappione A, Pugh-Bernard AE, Felgar RE, Looney RJ, et al. Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus. Arthritis Rheum 2004;50:3580-90.
20. Anolik JH, Campbell D, Felgar RE, Young F, Sanz I, Rosenblatt J, et al. The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus. Arthritis Rheum 2003;48:455-9.
21. Dunham J, et al. A longitudinal analysis of SL: Patients treated with rituximab: A comparison of B cell depleters to partial B cell depleters. Arthritis Rheum 2005 (in press).
22. Lipsky PE. Systemic lupus erythematosus: an autoimmune disease of B cell hyperactivity. Nat Immunol 2001;2:764-6.
23. McLaughlin P, Grillo-Lopez AJ, Link BK, Levy R, Czuczman MS, Williams ME, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998;16:2825-33.
24. D'Arcy CA, Mannik M. Serum sickness secondary to treatment with the murine-human chimeric antibody IDEC-C2B8 (rituximab). Arthritis Rheum 2001;44:1717-18.
25. Kami M, Hamaki T, Murashige N, Kishi Y, Kusumi E, Yuji K, et al. Safety of rituximab in lymphoma patients with hepatitis B or hepatitis C virus infection. Hematol J 2003;4:159-62.
26. Keane J. TNF-blocking agents and tuberculosis: new drugs illuminate an old topic. Rheumatology (Oxford) 2005;44:714-20 [Epub 1 March 2005].